CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is down 8.94% in post-market trading, falling to $3.26 from today's regular-session close of $3.58, on volume of 9,829 shares.
Why CLGN Is Moving
The after-hours decline follows a series of significant corporate developments:
- LightSolver Acquisition Completed: On September 3, 2026, CollPlant announced it had completed its acquisition of LightSolver, marking the company's entry into photonic computing and supercomputing markets.
- Board Appointment: On September 4, 2026, the company appointed Dr. Ruti Ben Shlomi to its Board of Directors following the closing of the LightSolver deal.
- Reverse Share Split Announced: On September 1, 2026, CollPlant announced a reverse share split, a corporate action typically used to boost a stock's price per share.
Background
The Nasdaq notified CollPlant in March 2026 that the company was not in compliance with minimum bid price requirements, which likely prompted the reverse share split effort. The stock had traded as low as $3.55 prior to today's session, reflecting ongoing pressure from delisting concerns.
CollPlant had previously operated exclusively in regenerative and aesthetic medicine, developing 3D bioprinted tissues and dermal fillers using its proprietary plant-based collagen technology. The LightSolver deal represents a significant strategic pivot into an entirely new sector.
The regular-hours session saw CLGN gain 0.85%, closing at $3.58, before the post-market pullback brought the price to $3.26.
What to Watch
Investors will likely monitor for additional details on the LightSolver integration and any further announcements regarding the company's dual presence in biotechnology and photonic computing sectors.